Nancy E, Katz is Cyanotech's newest Director, joining the company's board in October 2016. Chairman Davis stated enthusiastically in the company press release that Mrs Katz's...
"...significant experience as an executive and director of public companies will provide valuable insight to the Board and management in strategy development and other Company functions"
Davis' eloquent praise of Ms Katz's credentials ringed hopeful to shareholders, until Ms Katz's real world track record was reviewed by the J.F.C.S. "Department of Factual Verification"
Ms Katz has a seemingly impressive resume, including an important sounding title at a brand name company. Davis' praise for Ms Katz's credentials, however enthusiastic, is not supported by the historical record.
Ms Katz served as a Director and Board Member of Neurometrix (NURO). Ms Katz was also Director, President and CEO of Calypte Biomedical; impressive titles, adding to Davis' description of the Katz hire as though the Yankees had just hired Babe Ruth from the Red Sox.
Neurometrix trades around $0.66 per share, which is bad news for Cyanotech shareholders. On the other hand, the price per share is about 640x higher than Calyphyte's which trade OTC for around $.001 per share.
Unfortunately for shareholders and employees, Davis seems to have added another board member he feels he can easily influence ("bedazzle") with his extreme wealth, and new age spiritual save the planet posing.
KAILUA KONA, Hawaii (October 25, 2016) — The Board of Directors of Cyanotech Corporation (Nasdaq Capital Market: CYAN) has named Nancy Katz as a Director of the Company.
“We are pleased to welcome Ms. Katz to Cyanotech’s Board,” said Michael A. Davis, Chairman of the Board. “Her significant experience as an executive and director of public companies will provide valuable insight to the Board and management in strategy development and other Company functions.”
Ms. Katz served as Vice President, Consumer Marketing at Medtronic, Inc., a medical technology company from May 2011 to August 2014. From July 2005 to July 2010, she was Senior Vice President, Bayer Diabetes Care — North America. Prior to this position, she was President and Chief Executive Officer of Calypte Biomedical Corporation, a manufacturer of HIV diagnostics; President of Zila Pharmaceutical, Inc., a manufacturer of oral care products; and held senior marketing positions with the Lifescan division of Johnson & Johnson (blood glucose diabetes products), Schering-Plough Healthcare Products, and with American Home Products. She has previously served on the Boards of Directors of Neoprobe Corporation, Calypte Biomedical Corporation, LXN Corporation and Pepgen Corporation. She currently serves on the Board of NeuroMetrix, Inc.